Ultragenyx Pharmaceutical (UP0) Stock Statistics & Valuation Metrics

Ultragenyx Pharmaceutical has a market cap or net worth of CHF2.75B. The enterprise value is $3.68B.

Ultragenyx Pharmaceutical has ― shares outstanding. The number of shares has decreased by -2.65% in one year.

Ultragenyx Pharmaceutical’s return on equity (ROE) is 7.19 and return on invested capital (ROIC) is -43.53%.

The current PE Ratio of Ultragenyx Pharmaceutical is ―. Ultragenyx Pharmaceutical’s PEG ratio is 0.54.

In the last 12 months, Ultragenyx Pharmaceutical had revenue of 673.00M and earned -575.00M in profits. Earnings per share was -5.83.

In the last 12 months, operating cash flow was -496.52M and capital expenditures 9.32M, giving a free cash flow of -487.20M billion.

Ultragenyx Pharmaceutical pays an annual dividend of ―, resulting in a dividend yield of ―

Ultragenyx Pharmaceutical upcoming earnings date is Jul 30, 2026, TBA (Confirmed).

Ultragenyx Pharmaceutical as a current ratio of 2.48, with Debt / Equity ratio of -508.47%

In the past 12 months, Ultragenyx Pharmaceutical has paid 4.00M in taxes.

Ultragenyx Pharmaceutical EV to EBITDA ratio is -6.56, with an EV/FCF ratio of -6.59.

Ultragenyx Pharmaceutical has CHF413.00M in cash and marketable securities with CHF1.20B in debt, giving a net cash position of -CHF787.00M billion.

Gross margin is 83.57%, with operating margin of -79.49%, and net profit margin of -85.44%.

The average price target for Ultragenyx Pharmaceutical is CHF43.80, which is 11.43% higher than the current price. The consensus rating is Strong Buy